[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 351
Citations 0
Capitol Health Call
February 9, 2016

Senate Committee Investigates Price Hikes for Off-Patent Drugs

JAMA. 2016;315(6):549. doi:10.1001/jama.2016.0162

The Senate Special Committee on Aging is holding a series of hearings investigating sudden price increases for drugs that go off-patent.

“For many decades, federal policy has sought to strike the right balance between maintaining the incentives needed to promote innovation and the development of new drugs and keeping medicines affordable,” chair Susan Collins (R, Me) said in a statement at the first hearing (http://1.usa.gov/1YZGjnG). “That balance we have struck never anticipated companies acquiring off-patent drugs and then jacking up their prices to enormous heights….”

First Page Preview View Large
First page PDF preview
First page PDF preview
×